Description
Tukysa (tucatinib 50 mg/150 mg) is a kinase inhibitor approved for use in conjunction with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer. This includes those with brain metastases, previously treated with one or more anti-HER2-based regimens. Additionally, tucatinib, in combination with trastuzumab, is used to manage adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer. This indication applies to cases that have progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Posology & Administration:
Metastatic Breast Cancer: The recommended dosage of Tucatinib is 300 mg taken orally (by mouth) twice daily in combination with trastuzumab and capecitabine until there is evidence of disease progression or unacceptable toxicity.Unresectable or Metastatic Colorectal Cancer: The recommended dosage of Tucatinib is 300 mg taken orally (by mouth) twice daily in combination with trastuzumab until there is evidence of disease progression or unacceptable toxicity.
Swallow the tablets whole and do not chew, crush, or split before swallowing. Do not ingest tablets if it is broken, cracked, or not otherwise intact. Administer the Tukysa dosage around 12 hours apart and at the same time each day with or without a meal. If the patient vomits or misses a dose, the patient should take the next dose at its usual scheduled time. When given along with Tukysa, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes following a meal. Tukysa and capecitabine can be taken at the same time.